Product Description: Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Huang Z, et al. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol. 2022 Jun 27;13:924542./[2]Yunlong Shan, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 2581-2581.
CAS Number: 2350298-92-7
Molecular Weight: N/A
Compound Purity: 98.80
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: PD-1/PD-L1